These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Are we misunderstanding beta-blockers. Cruickshank JM Int J Cardiol; 2007 Aug; 120(1):10-27. PubMed ID: 17433471 [TBL] [Abstract][Full Text] [Related]
3. Current status of labetalol, the first alpha- and beta-blocking agent. Kanto JH Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):617-28. PubMed ID: 2867049 [TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of multiple action compounds. Prichard BN; Tomlinson B Z Kardiol; 1989; 78 Suppl 3():1-6. PubMed ID: 2573211 [TBL] [Abstract][Full Text] [Related]
6. New perspectives in cardiopulmonary therapeutics: receptor-selective adrenergic drugs. Adams HR J Am Vet Med Assoc; 1984 Nov; 185(9):966-74. PubMed ID: 6150925 [TBL] [Abstract][Full Text] [Related]
7. Effects of beta-blockers on glucose and lipid metabolism. Fonseca VA Curr Med Res Opin; 2010 Mar; 26(3):615-29. PubMed ID: 20067434 [TBL] [Abstract][Full Text] [Related]
8. Benefits of non-selective versus cardioselective beta-blockers in acute myocardial infarction in hypertensive patients. Hansen O; Johansson BW J Hypertens Suppl; 1993 Jun; 11(4):S55-60. PubMed ID: 8104242 [TBL] [Abstract][Full Text] [Related]
9. Pharmacology of combined alpha-beta-blockade. I. Louis WJ; McNeil JJ; Drummer OH Drugs; 1984; 28 Suppl 2():16-34. PubMed ID: 6151889 [TBL] [Abstract][Full Text] [Related]
10. Mode of action of beta-adrenergic blocking drugs in hypertension. Prichard BN; Owens CW Clin Physiol Biochem; 1990; 8 Suppl 2():1-10. PubMed ID: 1982756 [TBL] [Abstract][Full Text] [Related]
11. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046. Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223 [TBL] [Abstract][Full Text] [Related]
12. Human heart beta-adrenoceptors: beta1-adrenoceptor diversification through 'affinity states' and polymorphism. Molenaar P; Chen L; Semmler AB; Parsonage WA; Kaumann AJ Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1020-8. PubMed ID: 17714089 [TBL] [Abstract][Full Text] [Related]
13. Intrinsic cardiac neurons involved in cardiac regulation possess alpha 1-, alpha 2-, beta 1- and beta 2-adrenoceptors. Armour JA Can J Cardiol; 1997 Mar; 13(3):277-84. PubMed ID: 9117916 [TBL] [Abstract][Full Text] [Related]
14. [How and to what extent has beta-blocker treatment been established for chronic heart failure?]. Yokota Y J Cardiol; 1996 Aug; 28(2):99-112. PubMed ID: 8814528 [TBL] [Abstract][Full Text] [Related]
15. [Role of the L-arginine/nitric oxide system in the action of nebivolol]. Brodde OE; Philipp T Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442 [TBL] [Abstract][Full Text] [Related]
16. Labetalol in the treatment of angina pectoris. Kanto JH Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):166-74. PubMed ID: 2881899 [TBL] [Abstract][Full Text] [Related]
17. [New findings on the use of specific alpha-1 adrenergic blockers in the treatment of high blood pressure]. Horký K Vnitr Lek; 1991 Jun; 37(6):604-11. PubMed ID: 1680257 [TBL] [Abstract][Full Text] [Related]
18. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol. Ignarro LJ Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134 [TBL] [Abstract][Full Text] [Related]
19. ENOS is not activated by nebivolol in human failing myocardium. Brixius K; Song Q; Malick A; Boelck B; Addicks K; Bloch W; Mehlhorn U; Schwinger RH Life Sci; 2006 Aug; 79(13):1234-41. PubMed ID: 16716362 [TBL] [Abstract][Full Text] [Related]
20. [Antianginal and antiadrenergic therapy in acute coronary syndrome]. Raos V; Bergovec M Acta Med Croatica; 2004; 58(2):123-7. PubMed ID: 15208797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]